Northwest Bancshares, Inc. will release its third quarter 2026 financial results after market close on October 26, 2026. The company will hold a conference call and webcast on October 27 at 9:00 a.m. EST to discuss the results. Investors and the public can access the call and presentation slides via the company's website. Northwest Bancshares operates 153 financial centers across four states and is listed on NASDAQ under the ticker NWBI.
Northwest Bancshares, Inc. earnings call details provide context for financial sector activity. For readers following financials, here is Pluang's market snapshot as of Oct 06, 2026 02:42 WIB: Among 85 priced US financial stocks, 60 rose and 24 fell. Banco Santander SA (SAN) rose 4.08% to USD 13.90 with a typical hold time of 54 days and order activity of 64% sell. Coinbase Global, Inc. (COIN) increased 3.21% to USD 188.88, held typically for 78 days, with 59% sell orders. Msci Inc (MSCI) gained 3.13% to USD 552.75, held 82 days, with 72% sell orders.
Revvity's stock has surged 56.1% year-to-date, outperforming its industry and the S&P 500, driven by an 11% organic revenue growth in diagnostics, especially in reproductive health and immunodiagnostics. Analysts from William Blair and Zacks have upg...
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...
Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...
